A practical reference on bioavailability: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
Reviewed 2025-11-28. Anything still debated is marked as such rather than presented as settled.
Analytical methods for SR9009 typically rely on liquid chromatography coupled with tandem mass spectrometry. The technique can separate the parent compound from related substances and detect low concentrations in biological matrices. Urine and blood are common samples in anti-doping testing, while in vitro studies may use cell culture media. Rapid metabolism and low expected concentrations make method validation important for reliable identification. Exact metabolite patterns can vary by species and are not fully mapped.
Regulatory treatment of SR9009 reflects its investigational status. The compound has no approved human therapeutic indication, and sports authorities prohibit its use. It appears on anti-doping lists as a non-approved substance or metabolic modulator, depending on the list version. Products sold online as research chemicals are not quality-controlled medicines, so their identity and purity can differ from the label. Such products may also contain unlisted compounds, which complicates both testing and safety assessment.
Laboratory samples of SR9009 are typically supplied as a white to off-white powder. The compound dissolves readily in organic solvents such as dimethyl sulfoxide and ethanol, while its solubility in water is low. Because of this solubility profile, researchers often prepare concentrated stock solutions in an organic solvent before diluting them into aqueous assay buffers. Light exposure, moisture, and repeated freeze-thaw cycles can degrade many small molecules, so handling procedures usually aim to minimize these factors. Purity is commonly checked before use.
Storage conditions for research-grade SR9009 generally involve a freezer at approximately minus twenty degrees Celsius, sometimes lower for long-term preservation. Containers should remain tightly closed and protected from light. Desiccants may be used to limit moisture uptake. Solutions are often stored in aliquots to avoid repeated warming and cooling. Stability data for the compound under various conditions are limited, so laboratories typically follow supplier recommendations and verify performance through periodic analytical checks rather than assuming indefinite stability.
Identity and purity testing for SR9009 commonly uses liquid chromatography coupled with tandem mass spectrometry. This method separates the compound from matrix components and detects it by mass-to-charge transitions, providing sensitive and specific confirmation. Nuclear magnetic resonance spectroscopy can support structural identification, while high-performance liquid chromatography with ultraviolet detection may estimate purity. Because online products labeled as SR9009 may contain other substances or no active compound at all, independent verification is important in research settings. Certificates of analysis are useful but not a substitute for in-house testing.
| Property | Value | Notes |
|---|---|---|
| Regulatory status | Not approved for human use | Investigational status in most countries |
| Sports status | Prohibited by WADA | Classified as non-approved or metabolic modulator |
| Common analytical method | LC-MS/MS | Used for trace detection in biological samples |
| Typical test matrices | Urine and blood | Sample choice depends on testing program |
| Human trial data | None published | Effects and safety are not established |
SR9009 binds REV-ERB receptors and alters their repressive activity on target genes. This action can change transcription of genes involved in lipid handling, glucose metabolism, and mitochondrial function. In rodent studies, treated animals have shown changes in muscle oxidative capacity and exercise performance, though effects vary by dose, duration, and model. The precise molecular steps connecting receptor binding to whole-body outcomes are still an active area of investigation. Findings in animals do not automatically translate to humans.
Because REV-ERB receptors are core clock components, SR9009 has been examined for effects on daily rhythms as well as metabolism. Research has explored whether the compound can shift or reinforce circadian gene expression in tissues such as liver and muscle. Some studies report improved metabolic markers in obese or diabetic mice, while others show context-dependent responses. Questions remain about which effects are direct, which are secondary to timing, and how they might differ across species.
Preclinical reports describe effects on exercise endurance, mitochondrial content, and lipid profiles in rodents, but these findings come from specific experimental conditions. Many studies use high doses or delivery methods that may not translate directly to human use. SR9009 has been reported to have low oral bioavailability and a short half-life, which complicates interpretation of oral dosing studies. It is not established as safe or effective for any indication. Literature discussions often separate its pharmacological mechanism from unverified claims made in fitness and supplement markets.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. It is not an approved medicine and has no established human therapeutic use. The compound appears in scientific literature as a tool for probing circadian and metabolic regulation. Online sellers often label it as a research chemical, sometimes using the nickname Stenabolic. Its chemical identity is distinct from selective androgen receptor modulators, stimulants, and peroxisome proliferator-activated receptor delta agonists. Researchers use it mainly in cell and animal experiments.
At the molecular level, SR9009 binds REV-ERBα and REV-ERBβ and alters their repressive activity on target genes. These nuclear receptors help regulate the circadian clock, lipid synthesis, glucose metabolism, and inflammatory pathways. By changing transcription, the compound can shift the timing or magnitude of downstream metabolic processes in model systems. It does not act through androgen receptors or adenosine receptors, which distinguishes it from several substances sold for athletic performance. Whether the same transcriptional changes occur in humans at tolerable exposures remains an open question because controlled human studies are lacking.
In rodent studies, SR9009 has been reported to increase mitochondrial content in skeletal muscle and improve exercise endurance under some conditions. These findings led to popular descriptions such as an exercise mimetic, although that term oversimplifies the biology. Effects vary by dose, timing, tissue, and model. The compound's influence on circadian pathways means that time of administration can matter in experiments. Whether similar metabolic changes occur in humans remains largely unexplored in controlled published trials.
Pharmacokinetic data for SR9009 are limited in published literature. Some reports indicate low oral bioavailability and rapid clearance in animals, which complicates interpretation of exposure and effect. Researchers often use injected routes in preclinical work to achieve measurable systemic levels. Analytical studies rely on mass spectrometry to detect the parent compound and its metabolites. Questions about tissue distribution, active metabolites, and long-term consequences remain open. Species differences in metabolism can affect observed half-life and target engagement.
SR9009 is a synthetic small molecule studied as a REV-ERB agonist. REV-ERBα and REV-ERBβ are nuclear receptors that help regulate circadian rhythms and metabolic gene expression. The compound was identified in academic screening efforts to find synthetic ligands for these receptors. In cell and animal studies, SR9009 alters transcription of genes involved in lipid and glucose metabolism, and it can shift circadian behavior. It is not an approved therapeutic agent.
Mechanistically, SR9009 binds the ligand-binding domain of REV-ERBα/β and enhances recruitment of corepressor complexes. This represses target genes rather than activating them. Because REV-ERB proteins normally compete with ROR proteins at shared response elements, the net effect depends on tissue and timing. Researchers use SR9009 to probe how nuclear receptor signaling links the clock to metabolism, inflammation, and muscle biology. Findings are largely preclinical, and the precise contribution of each receptor subtype remains under study.
Most hyaluronic acid injectable fillers are cross-linked using chemicals such as 1,4 butanediol ether (BDDE) to enhance their stability and resistance to enzymatic degradation. Cross-linking significantly improves pharmokinetics and allows the filler to remain in the body for a longer duration. However, concerns have been raised regarding the long-term safety of BDDE, which remains incompletely understood. A 2024 review reports that the long-lasting side effects and potential harm of BDDE has caused allergic reactions in patients. A 2015 study found that 34.3% of patients in a cohort of 452 experienced allergic reactions associated with BDDE exposure. Self-Cross-Linkable Hyaluronic Acid
=== How does dentinal bonding occur? === Dentin bonding refers to process of bonding a resin to conditioned dentin, where mineral component is replaced with resin monomers to form a biocomposite comprising dentin collagen and cured resin. The adhesive-dentin interface forms a tight and permanent bond between dentin and composite resins. It can be accomplished by either etch-and-rinse (total etch) or self-etch adhesives. In etch-and rinse, acid will dissolve the minerals to a certain depth and leaves the highly porous dentinal collagen network suspended in water. Then, the collagen network is infiltrated with resin monomers. After chemical polymerization of these monomers happen, activated by light cure, it will result in a polymer-collagen biocomposite, commonly known as the hybrid layer:
==== Other procedures ==== Orthokeratology is a method using specialized hard or rigid gas-permeable contact lenses to transiently reshape the cornea in order to improve the refractive state of the eye or reduce the need for eyeglasses and contact lenses. In 2009, researchers at the University of Pittsburgh Medical center demonstrated that stem cell collected from human corneas can restore transparency without provoking a rejection response in mice with corneal damage. For corneal epithelial diseases such as Stevens Johnson Syndrome, persistent corneal ulcer etc., the autologous contralateral (normal) suprabasal limbus derived in vitro expanded corneal limbal stem cells are found to be effective as amniotic membrane based expansion is controversial. For endothelial diseases, such as bullous keratopathy, cadaver corneal endothelial precursor cells have been proven to be efficient. Recently emerging tissue engineering technologies are expected to be capable of making one cadaver-donor's corneal cells be expanded and be usable in more than one patient's eye. One such technique has been reported to be safe and efficacious in a clinical pilot study with long term follow-up.
Sources: en.wikipedia.org
The secondary drying phase aims to remove unfrozen water molecules, since the ice was removed in the primary drying phase. This part of the freeze-drying process is governed by the material's adsorption isotherms. In this phase, the temperature is raised higher than in the primary drying phase, and can even be above 0 °C (32 °F), to break any physico-chemical interactions that have formed between the water molecules and the frozen material. Usually the pressure is also lowered in this stage to encourage desorption (typically in the range of microbars, or fractions of a pascal). However, there are products that benefit from increased pressure as well. After the freeze-drying process is complete, the vacuum is usually broken with an inert gas, such as nitrogen, before the material is sealed. At the end of the operation, the final residual water content in the product is extremely low, around 1–4%.
=== Hostage-taking === According to the Human Rights Watch, the Houthis also use hostage taking as a tactic to generate profit. Human Rights Watch documented 16 cases in which Houthi authorities held people unlawfully, in large part to extort money from relatives or to exchange them for people held by opposing forces.
=== Elimination of suprabony fibrous and firm pockets === Gingivectomy is the primary treatment method available in reducing the pocket depths of patients with periodontitis and suprabony pockets. In a retrospective comparison between different treatment approach to periodontitis management based on the initial and final gingival health, conventional gingivectomy was proven to be more successful in reducing pocket depths and inflammation compared to non-surgical treatments in pockets measured 3mm or more. Removal of suprabony deep pockets will allow better visibility and access for the removal of calculus. As a result, this provides a suitable environment for the healing of the gingiva and the physiological contour of the gingiva to be restored.
Slurry ice can boost by up to 200% the cooling efficiency of existing cooling or freezing brine systems without any major changes to the system (i.e. heat exchanger, pipes, valves), and reduce the amount of energy consumption used for pumping.
Sources: en.wikipedia.org
== Organization and leadership == The National Institutes of Health (NIH) is composed of 27 Institutes and Centers, most of which include research programs led by a Scientific Director and conducted by federal researchers and their trainees at one of several NIH campus locations. Collectively, these research programs encompass the Intramural Research Program (IRP). The IRP includes the United States National Library of Medicine, an international resource for researchers, and the NIH Clinical Center, the world's largest clinical research hospital. Intramural researchers are affiliated with individual Laboratories, Branches or Centers, which are typically organized around common thematic research goals and approaches, much like a department or center at an academic institution. Within these larger structures, Principal Investigators run Sections or Units devoted to their independent research goals. Core facilities, supported by staff scientists and clinicians, are among the shared resources available to IRP researchers. Scientific interests are not bound by the organizational structure. There exists a full spectrum of scientific interest groups (called SIGs) that brings researchers from different Institutes and Centers together around common areas of scientific interest where ideas can be shared and collaborations initiated. In addition, institutes come together to work cooperatively on major initiatives focused on unraveling the complexities of disease.
Iodoacetamide (IAA) is an organic compound with the chemical formula ICH2CONH2. It is an alkylating agent used for peptide mapping purposes. Its actions are similar to those of iodoacetate. It is commonly used to bind covalently with the thiol group of cysteine so the protein cannot form disulfide bonds. It is also used in ubiquitin studies as an inhibitor of deubiquitinase enzymes (DUBs) because it alkylates the cysteine residues at the DUB active site.
== History == Transaid was founded in 1998 by Save the Children, the Chartered Institute of Logistics and Transport (CILT), and its patron, Anne, Princess Royal. It is a UK‑based international development charity focused on transforming lives through safe, available, and sustainable transport in sub‑Saharan Africa. The charity operates multiple programmes in several countries, working with governments, communities, and industry partners to improve road safety, transport management, and access to healthcare. In recent years, Transaid has been active in motorcycle helmet safety in Kenya through its Kenya National Helmet Wearing Coalition, working with the FIA Foundation and others to build enforcement of helmet standards, establish awareness among riders, and to set up a helmet testing laboratory in East Africa. The charity has also launched its Christmas Appeal 2025 to raise funds from individuals and businesses for road safety and healthcare access across sub‑Saharan Africa; in that appeal, it reported having trained over 9,000 professional drivers and riders, delivered thousands of eye tests, and supported minibus‑taxis adopting safety charters. Additionally in early 2025, Princess Anne opened the new London office of Arbuthnot Latham, a corporate partner of Transaid, emphasising the strengthening of corporate backing and visibility for the charity.
Traditional kefir is fermented at ambient temperatures, generally overnight. Fermentation of the lactose yields a sour, carbonated, slightly alcoholic beverage, with a consistency and taste similar to drinkable yogurt. The kefir grains initiating the fermentation are initially created by auto-aggregations of Lactobacillus kefiranofaciens and Maudiozyma turicensis or M. humilis, where multiple biofilm producers cause the surfaces to adhere which form a three dimensional microcolony. The biofilm is a matrix of heteropolysaccharides called kefiran, which is composed of equal proportions of glucose and galactose. It resembles small cauliflower grains, with color ranging from white to creamy yellow. A complex and highly variable symbiotic community can be found in these grains, which can include acetic acid bacteria (such as Acetobacter aceti and Acetobacter rasens), yeasts (such as Kluyveromyces lactis, K. marxianus, Saccharomyces cerevisiae, M. turicensis) and a number of Lactobacillus species, such as L. parakefiri, L. kefiranofaciens (and subsp. kefirgranum), L. kefiri, L. brevis, etc. While some microbes predominate, Lactobacillus species are always present. The microbe flora can vary between batches of kefir due to factors such as the kefir grains rising out of the milk while fermenting or curds forming around the grains, as well as temperature. Additionally, Tibetan kefir composition differs from that of the Russian kefir, Irish kefir, Taiwan kefir and Turkey fermented beverage with kefir.
=== Pharmacokinetics === N-Desalkylflurazepam has an elimination half-life of 47–150 hours (up to 200 hours in some healthy volunteers), with an average of ~71 hours. Peak blood concentrations of N-Desalkylflurazepam is reached at 10.2 h following a single 15 mg dose of Flurazepam, typically around ~10-20.4 ng/mL. Its plasma levels are unreliable amongst patients, and are largely influenced by liver disease, liver enzyme inducers and inhibitors, as well as old age (in men).
Sources: en.wikipedia.org
No. It is an investigational compound without approved therapeutic indications. It is sold for research purposes only in many jurisdictions.
Sports authorities prohibit it because it is not approved for human use and has potential performance-enhancing effects. It appears on anti-doping lists under non-approved or metabolic modulator categories.
Detection usually uses liquid chromatography-tandem mass spectrometry. The method targets the parent compound or its metabolites in urine or blood.
Research-grade SR9009 is typically stored frozen at about minus twenty degrees Celsius, protected from light and moisture. Stock solutions are often kept in aliquots to avoid repeated freeze-thaw cycles. Specific storage conditions should follow the supplier's documentation.